G.M. Mondellini
Papers
1
Total Citations
6
H-Index
1
About
G.M. Mondellini is a clinical researcher whose work focuses on improving the early detection and monitoring of prostate cancer recurrence. Their primary research area centers on the use of novel biomarkers, particularly the isoform [-2]proPSA (p2PSA), to enhance the sensitivity and specificity of prostate cancer diagnostics. Mondellini’s major contribution is demonstrating that p2PSA can predict biochemical recurrence (BCR) of prostate cancer after radical prostatectomy significantly earlier than the traditional total prostate-specific antigen (PSA) test. This finding, published in a 2019 observational prospective cohort study (which has garnered 6 citations), addresses a critical unmet clinical need by enabling earlier identification of clinically significant recurrent disease. By shifting the focus from total PSA to more specific molecular markers, Mondellini’s work has the potential to improve patient outcomes through more timely interventions. Their research underscores a commitment to advancing precision oncology, offering a promising tool for urologists and oncologists striving to personalize follow-up care for prostate cancer survivors.
Research Focus
Key Achievements
Top Papers
- 1